Literature DB >> 33858515

Brain insulin signaling and cerebrovascular disease in human postmortem brain.

Zoe Arvanitakis1, Ana W Capuano2, Hoau-Yan Wang3,4, Julie A Schneider2, Alifiya Kapasi2, David A Bennett2, Rexford S Ahima5, Steven E Arnold6.   

Abstract

Insulin is an important hormone for brain function, and alterations in insulin metabolism may be associated with neuropathology. We examined associations of molecular markers of brain insulin signaling with cerebrovascular disease. Participants were enrolled in the Religious Orders Study (ROS), an ongoing epidemiologic community-based, clinical-pathologic study of aging from across the United States. Using cross-sectional analyses, we studied a subset of ROS: 150 persons with or without diabetes, matched 1:1 by sex on age-at-death and education. We used ELISA, immunohistochemistry, and ex vivo stimulation with insulin, to document insulin signaling in postmortem midfrontal gyrus cortex tissue. Postmortem neuropathologic data identified cerebrovascular disease including brain infarcts, classified by number (as none for the reference; one; and more than one), size (gross and microscopic infarcts), and brain region/location (cortical and subcortical). Cerebral vessel pathologies were assessed, including severity of atherosclerosis, arteriolosclerosis, and amyloid angiopathy. In separate regression analyses, greater AKT1 phosphorylation at T308 following ex vivo stimulation with insulin (OR = 1.916; estimate = 0.650; p = 0.007) and greater pS616IRS1 immunolabeling in neuronal cytoplasm (OR = 1.610; estimate = 0.476; p = 0.013), were each associated with a higher number of brain infarcts. Secondary analyses showed consistent results for gross infarcts and microinfarcts separately, but no other association including by infarct location (cortical or subcortical). AKT S473 phosphorylation following insulin stimulation was associated with less amyloid angiopathy severity, but not with other vessel pathology including atherosclerosis and arteriolosclerosis. In summary, insulin resistance in the human brain, even among persons without diabetes, is associated with cerebrovascular disease and especially infarcts. The underlying pathophysiologic mechanisms need further elucidation. Because brain infarcts are known to be associated with lower cognitive function and dementia, these data are relevant to better understanding the link between brain metabolism and brain function.

Entities:  

Keywords:  Amyloid angiopathy; Atherosclerosis; Brain; Diabetes; Infarct; Insulin

Year:  2021        PMID: 33858515     DOI: 10.1186/s40478-021-01176-9

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  26 in total

1.  Brain Insulin Signaling, Alzheimer Disease Pathology, and Cognitive Function.

Authors:  Zoe Arvanitakis; Hoau-Yan Wang; Ana W Capuano; Amber Khan; Bouchra Taïb; Frederick Anokye-Danso; Julie A Schneider; David A Bennett; Rexford S Ahima; Steven E Arnold
Journal:  Ann Neurol       Date:  2020-07-27       Impact factor: 10.422

2.  FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium.

Authors:  S Donnini; S Cantara; L Morbidelli; A Giachetti; M Ziche
Journal:  Cell Death Differ       Date:  2006-01-27       Impact factor: 15.828

3.  Early cardiovascular changes occurring in diet-induced, obese insulin-resistant rats.

Authors:  Barbara Huisamen; Daneel Dietrich; Nicole Bezuidenhout; John Lopes; Brian Flepisi; Dee Blackhurst; Amanda Lochner
Journal:  Mol Cell Biochem       Date:  2012-05-26       Impact factor: 3.396

4.  Cerebral amyloid angiopathy pathology and cognitive domains in older persons.

Authors:  Zoe Arvanitakis; Sue E Leurgans; Zhenxin Wang; Robert S Wilson; David A Bennett; Julie A Schneider
Journal:  Ann Neurol       Date:  2010-11-08       Impact factor: 10.422

5.  Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: correlation with Alzheimer's neuropathology.

Authors:  Milos D Ikonomovic; Elliott J Mufson; Joanne Wuu; Elizabeth J Cochran; David A Bennett; Steven T DeKosky
Journal:  J Alzheimers Dis       Date:  2003-02       Impact factor: 4.472

Review 6.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

7.  Diabetes is associated with cerebrovascular but not Alzheimer's disease neuropathology.

Authors:  Erin L Abner; Peter T Nelson; Richard J Kryscio; Frederick A Schmitt; David W Fardo; Randall L Woltjer; Nigel J Cairns; Lei Yu; Hiroko H Dodge; Chengjie Xiong; Kamal Masaki; Suzanne L Tyas; David A Bennett; Julie A Schneider; Zoe Arvanitakis
Journal:  Alzheimers Dement       Date:  2016-01-23       Impact factor: 21.566

Review 8.  Insulin in the brain: sources, localization and functions.

Authors:  Rasoul Ghasemi; Ali Haeri; Leila Dargahi; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2012-09-07       Impact factor: 5.590

9.  Relation of cerebral vessel disease to Alzheimer's disease dementia and cognitive function in elderly people: a cross-sectional study.

Authors:  Zoe Arvanitakis; Ana W Capuano; Sue E Leurgans; David A Bennett; Julie A Schneider
Journal:  Lancet Neurol       Date:  2016-06-14       Impact factor: 44.182

10.  Parahippocampal gyrus expression of endothelial and insulin receptor signaling pathway genes is modulated by Alzheimer's disease and normalized by treatment with anti-diabetic agents.

Authors:  P Katsel; P Roussos; M S Beeri; M A Gama-Sosa; S Gandy; S Khan; V Haroutunian
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

View more
  1 in total

Review 1.  Beyond amyloid: Immune, cerebrovascular, and metabolic contributions to Alzheimer disease in people with Down syndrome.

Authors:  Alessandra C Martini; Thomas J Gross; Elizabeth Head; Mark Mapstone
Journal:  Neuron       Date:  2022-04-25       Impact factor: 18.688

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.